White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation

Alzheimer’s Research & Therapy

Lucilla Parnetti¹  Henrik Zetterberg²  Kaj Blennow²  Hayrettin Tumani³  Sanna-Kaisa Herukka⁴  Markus Otto⁵  Jens Wiltfang⁶  Piotr Lewczuk⁷  Alberto Lleó⁸  Armand Perret-Liaudet⁹  Charlotte E. Teunissen^1,10  Martin R. Turner^1,11  Marcel M. Verbeek^1,12  Sebastiaan Engelborghs^1,13  Sylvain Lehmann^1,14 

[1] Center for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, Department of Medicine, University of Perugia;Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital;Department of Neurology, CSF Laboratory, MS Outpatient Unit, University Hospital of Ulm;Department of Neurology, University of Eastern Finland and Kuopio University Hospital;Department of Neurology, University of Ulm;Department of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg-August University;Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen;Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona;Neurobiology Laboratory, Department of Biochemistry and Molecular Biology, Hospices Civils de Lyon;Neurochemistry Lab and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience, VU University Medical Center Amsterdam;Nuffield Department of Clinical Neurosciences, University of Oxford;Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Departments of Neurology and Laboratory Medicine, Radboud Alzheimer Centre;Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp;Université de Montpellier, University Hospital, INSERM U1183;

关键词: Society;    Education Biomarkers;    Neurology;    Cerebrospinal fluid;    Body fluids;    Biomarker discovery;   

DOI  :  10.1186/s13195-018-0359-x

来源: DOAJ

【 摘 要 】

Abstract Body fluid biomarkers have great potential for different clinical purposes, including diagnosis, prognosis, patient stratification and treatment effect monitoring. This is exemplified by current use of several excellent biomarkers, such as the Alzheimer’s disease cerebrospinal fluid (CSF) biomarkers, anti-neuromyelitis optica antibodies and blood neurofilament light. We still, however, have a strong need for additional biomarkers and several gaps in their development and implementation should be filled. Examples of such gaps are i) limited knowledge of the causes of neurological diseases, and thus hypotheses about the best biomarkers to detect subclinical stages of these diseases; ii) the limited success translating discoveries obtained by e.g. initial mass spectrometry proteomic low-throughput studies into immunoassays for widespread clinical implementation; iii) lack of interaction among all stakeholders to optimise and adapt study designs throughout the biomarker development process to medical needs, which may change during the long period needed for biomarker development. The Society for CSF Analysis and Clinical Neurochemistry (established in 2015) has been founded as a concerted follow-up of large standardisation projects, including BIOMARKAPD and SOPHIA, and the BioMS-consortium. The main aims of the CSF society are to exchange high level international scientific experience, to facilitate the incorporation of CSF diagnostics into clinical practice and to give advice on inclusion of CSF analysis into clinical guidelines. The society has a broad scope, as its vision is that the gaps in development and implementation of biomarkers are shared among almost all neurological diseases and thus they can benefit from the activities of the society.

【 授权许可】

Unknown